R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
M.H. Qazilbash,Rima M. Saliba,Chitra Hosing,Floralyn Mendoza,S. Qureshi,Donna M. Weber,Michael Wang,Thuy Flosser,Daniel R. Couriel,M. de Lima,Partow Kebriaei,U. Popat,Amin M. Alousi,Richard E. Champlin,Sergio Giralt +14 more
TL;DR: HDR and autologous transplant is safe and feasible in elderly myeloma patients and patients with relapsed disease at transplant, and an interval of >12 months between diagnosis and autotransplant, had a shorter OS.
Journal ArticleDOI
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
Mohamed A. Kharfan-Dabaja,Ambuj Kumar,Ernesto Ayala,Mahmoud Aljurf,Taiga Nishihori,Rebecca A. Marsh,Lauri Burroughs,Navneet S. Majhail,A. Samer Al-Homsi,Zaid S. Al-Kadhimi,Merav Bar,Alice Bertaina,Jaap Jan Boelens,Richard E. Champlin,Sonali Chaudhury,Zachariah DeFilipp,Bhagirathbhai Dholaria,Areej El-Jawahri,Suzanne Fanning,Ellen Fraint,Usama Gergis,Sergio Giralt,Betty K. Hamilton,Shahrukh K. Hashmi,Biljana Horn,Yoshihiro Inamoto,David A. Jacobsohn,Tania Jain,Laura Johnston,Abraham S. Kanate,Ankit Kansagra,Adetola A. Kassim,Leslie S. Kean,Carrie L. Kitko,Jessica Knight-Perry,Joanne Kurtzberg,Hien D. Liu,Margaret L. MacMillan,Zahra Mahmoudjafari,Marco Mielcarek,Mohamad Mohty,Arnon Nagler,Eneida R. Nemecek,Timothy S. Olson,Betul Oran,Miguel-Angel Perales,Susan E. Prockop,Michael A. Pulsipher,Iskra Pusic,Marcie L. Riches,Cesar Rodriguez,Rizwan Romee,Gabriela Rondon,Ayman Saad,Nina Shah,Peter J. Shaw,Shalini Shenoy,Jorge Sierra,Julie Talano,Michael R. Verneris,Paul Veys,John E. Wagner,Bipin N. Savani,Mehdi Hamadani,Paul A. Carpenter +64 more
TL;DR: The authors surveyed a panel of allogeneic hematopoietic cell transplantation (allo-HCT) experts in an attempt to standardize these definitions, finding consensus for neutrophil and platelet recovery, graft rejection, graft failure, poor graft function, and donor chimerism but not for delayed engraftment.
Journal ArticleDOI
Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma
Yago Nieto,Benigno C. Valdez,Peter F. Thall,Roy B. Jones,Wei Wei,Alan L. Myers,Chitra Hosing,Sairah Ahmed,Uday R. Popat,Elizabeth J. Shpall,Muzaffar H. Qazilbash,Alison M. Gulbis,Paolo Anderlini,Nina Shah,Qaiser Bashir,Amin M. Alousi,Yasuhiro Oki,Michelle A. Fanale,Bouthaina S. Dabaja,Chelsea C. Pinnix,Richard E. Champlin,Borje S. Andersson +21 more
TL;DR: More active high‐dose chemotherapy regimens are needed for refractory lymphomas after observations that vorinostat induced DNA methyltransferase up‐regulation, which could be preclinically abrogated by azacitidine, increasing tumor‐cell kill.
Journal ArticleDOI
Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.
Desiree Jones,Elisabeth G. Vichaya,Xin Shelley Wang,Loretta A. Williams,Nina Shah,Sheeba K. Thomas,Valen E. Johnson,Valen E. Johnson,Richard E. Champlin,Charles S. Cleeland,Tito R. Mendoza +10 more
TL;DR: The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.
Journal ArticleDOI
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
Chitra Hosing,Rima M. Saliba,Grace-Julia Okoroji,Uday R. Popat,Daniel R. Couriel,T. Ali,L. De Padua Silva,Partow Kebriaei,Amin M. Alousi,M. de Lima,Muzaffar H. Qazilbash,Paolo Anderlini,Sergio Giralt,Richard E. Champlin,Issa F. Khouri +14 more
TL;DR: Patients with relapsed lymphomas who are older than 65 years at the time of high-dose chemotherapy and autologous progenitor cell transplantation should be considered transplant candidates, particularly if they have chemosensitive disease and normal LDH levels at thetime of transplantation.